Delving into the Latest Updates on 苏州丁孚靶点生物技术有限公司 with Synapse

主要目的：评价DF003单药治疗晚期恶性实体瘤或非霍奇金淋巴瘤受试者的安全性和耐受性，以评估MTD；次要目的：评估DF003单药治疗晚期恶性实体瘤或非霍奇金淋巴瘤受试者的PK特征；评估DF003单药治疗晚期恶性实体瘤或非霍奇金淋巴瘤受试者的PK特征；评价DF003单药治疗晚期恶性实体瘤或非霍奇金淋巴瘤受试者的初步抗肿瘤活性；评价DF003的免疫原性

开始日期2022-07-11

申办/合作机构

苏州丁孚靶点生物技术有限公司

CTR20210299 / Recruiting临床1期

一项评估DF203在晚期实体瘤患者中的安全性、耐受性、药代动力学及抗肿瘤疗效的多中心、单臂、开放、I期临床试验

主要目的：评价DF203在晚期实体瘤患者中的安全性及耐受性，并确定最大耐受剂量（MTD）以及Ⅱ期推荐给药剂量（RPⅡD）次要目的：评价DF203在晚期实体瘤患者中的药代动力学（PK）特征；评价DF203在晚期实体瘤患者中的初步抗肿瘤疗效。探索性目的：基于外周血中特异性免疫细胞因子和特异性T细胞以及肿瘤组织中特异性T细胞和基因组的相关变化，评估DF203在晚期实体瘤患者中的药效动力学（PD）特征。

开始日期2021-04-02

申办/合作机构

苏州丁孚靶点生物技术有限公司

100 项与苏州丁孚靶点生物技术有限公司相关的临床结果

登录后查看更多信息

0 项与苏州丁孚靶点生物技术有限公司相关的专利（医药）

登录后查看更多信息

5

项与苏州丁孚靶点生物技术有限公司相关的文献（医药）

2019-06-01·Cancer Cell

Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

Article

作者: Luan, Yan ; Ren, Zhenhua ; Liu, Zhida ; Xu, Ting ; Fu, Kai ; Dong, Chunbo ; Zhang, Anli ; Fu, Yang-Xin ; Qiao, Jian ; Han, Chuanhui ; Moore, Casey ; Wang, Yang ; Peng, Jianjian

Increasing evidence demonstrates that interleukin-10 (IL-10), known as an immunosuppressive cytokine, induces antitumor effects depending on CD8⁺ T cells. However, it remains elusive how immunosuppressive effects of IL-10 contribute to CD8⁺ T cell-mediated antitumor immunity. We generated Cetuximab-based IL-10 fusion protein (CmAb-(IL10)₂) to prolong its half-life and allow tumor-targeted delivery of IL-10. Our results demonstrated potent antitumor effects of CmAb-(IL10)₂ with reduced toxicity. Moreover, we revealed a mechanism of CmAb-(IL10)₂ preventing dendritic cell (DC)-mediated CD8⁺ tumor-infiltrating lymphocyte apoptosis through regulating IFN-γ production. When combined with immune checkpoint blockade, CmAb-(IL10)₂ significantly improves antitumor effects in mice with advanced tumors. Our findings reveal a DC-regulating role of IL-10 to potentiate CD8⁺ T cell-mediated antitumor immunity and provide a potential strategy to improve cancer immunotherapy.

2017-07-01·Cancer Immunology Research1区 · 医学

Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression

1区 · 医学

Article

作者: Sun, Zhichen ; Xue, Diyuan ; Fu, Yang-Xin ; Xu, Hairong ; Liao, Jing ; Liu, Xiaojuan ; Yang, Kaiting ; Peng, Hua ; Luan, Yan ; Ren, Zhenhua

AbstractAnti-hCD20 is a therapeutic mAb that is clinically used to treat B-cell lymphoma. Some lymphomas are resistant to anti-hCD20; others relapse after treatment with anti-hCD20. Using a syngeneic immunocompetent mouse model, we observed that targeting lymphoma with interferon-α (IFNα) abolished resistance of B-cell lymphoma to anti-CD20 while limiting interferon (IFN)-associated systemic toxicity in the host. Control of tumors by a fusion of anti-CD20 and IFNα (anti–CD20-IFNα) depended on existing tumor-infiltrating CD8+ T cells. Although lymphomas were resistant to IFN-directed killing, IFN-exposed tumor cells became the dominant antigen-presenting cells (APC) for the reactivation of tumor-infiltrating CD8+ T cells that then controlled those lymphomas. Anti–CD20-IFNα also abolished checkpoint blockade resistance in advanced B-cell lymphoma. Our findings indicate that anti–CD20-IFNα eradicates B-cell lymphoma by employing tumor cells as APCs to reactivate tumor-infiltrating CD8+ T cells and synergizing with anti–PD-L1 treatment. Cancer Immunol Res; 5(7); 560–70. ©2017 AACR.

2017-01-01·Clinical Cancer Research1区 · 医学

CTLA-4 Limits Anti-CD20–Mediated Tumor Regression

1区 · 医学

Article

作者: Ren, Zhenhua ; Liao, Jing ; Liang, Yong ; Liu, Zhida ; Guo, Jingya ; Peng, Hua ; Liu, Xiaojuan ; Fu, Yang-Xin ; Sun, Zhichen ; Luan, Yan

AbstractPurpose: The inhibition of tumor growth by anti-CD20 antibody (Ab) treatment is mediated by Ab- and complement-dependent cytotoxicity in xenograft tumor models. In addition, anti-CD20 therapy for B-cell lymphoma can result in intrinsic and extrinsic tumor resistance to further Ab treatment. However, adaptive immune response–related resistance has not been well studied in anti-CD20–mediated tumor control, and adaptive immunity has long been underestimated. The purpose of this study was to explore whether T cells are involved in mediating the effects of anti-CD20 therapy and what factors contribute to adaptive immune response–related resistance.Experimental Design: Using a syngeneic mouse B-cell lymphoma model, we investigated the role of CD8+ T cells in anti-CD20–mediated tumor regression. Furthermore, we revealed how the tumor-specific T-cell response was initiated by anti-CD20. Finally, we studied adaptive immune response–related resistance in advanced B-cell lymphoma.Results: CD8+ T cells played an essential role in anti-CD20–mediated tumor regression. Mechanistically, anti-CD20 therapy promoted dendritic cell (DC)-mediated cross-presentation. Importantly, macrophages were also necessary for the increase in the tumor-specific CTL response after anti-CD20 treatment, via the production of type I IFN to activate DC function. Furthermore, adaptive resistance is gradually developed through the CTLA-4 pathway in Treg cells in larger lymphomas. Further blockade of CTLA-4 can synergize with anti-CD20 treatment in antitumor activities.Conclusions: The therapeutic function of anti-CD20 depends on tumor-specific CD8+ T-cell responses initiated by anti-CD20 through macrophages and DCs. CTLA-4 blockade can synergize with anti-CD20 to overcome adaptive immune response–related resistance in advanced B-cell lymphoma. Clin Cancer Res; 23(1); 193–203. ©2016 AACR.

100 项与苏州丁孚靶点生物技术有限公司相关的药物交易

登录后查看更多信息

100 项与苏州丁孚靶点生物技术有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

11

2

临床前

临床1期

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

DF003 ( 4-1BB )	非霍奇金淋巴瘤更多	临床1期
重组抗人EGFR抗体/IL-10双特异Fc融合蛋白(苏州丁孚靶点生物技术有限公司) ( EGFR x IL-10R )	晚期恶性实体瘤更多	临床1期
DF201	肿瘤更多	临床前
DF004(Dingfu Biotarget) ( OX40 )	肿瘤更多	临床前
DF016(Dingfu Biotarget)	肿瘤更多	药物发现